mmu-miR-186-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

mmu-miR-186-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

mmu-miR-378a-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5′ end, 4 phosphorothioates at the 3′ end, 3′ end cholesterol group, and full-length nucleotide 2′-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, […]

mmu-miR-378a-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5′ end, 4 phosphorothioates at the 3′ end, 1 cholesterol group at the 3′ end, and full-length nucleotide 2′-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their […]

mmu-miR-378a-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2′-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

mmu-miR-378a-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

MMUT Human Pre-designed siRNA Set A contains three designed siRNAs for MMUT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MMV019313 is a potent, non-bisphosphonate inhibitor of farnesyl/geranylgeranyl diphosphate synthase (FPPS/GGPPS) with an IC50 of 0.82 µM. MMV019313 has activity against P. falciparum (Parasite)[1].

MMV688533 is an antimalarial agent with rapid anti-plasmodial activity and effective single-dose activity against Plasmodium falciparum infection in humanized mouse models. MMV688533 can inhibit the activity of asexual blood stage parasites with an IC50 value of 1.3 nM. MMV688533 exhibits excellent pharmacokinetic properties and safety[1].

Mn(II)-DO3A sodium is a Mn(II) complex and a potential alternative to Gd-based MRI contrast agents[1].

Mn(II)-DO3A sodium is a Mn(II) complex and a potential alternative to Gd-based MRI contrast agents[1].

Mn(II)-DO3A sodium is a Mn(II) complex and a potential alternative to Gd-based MRI contrast agents[1].

Mn(II)-DO3A sodium is a Mn(II) complex and a potential alternative to Gd-based MRI contrast agents[1].

Mn(II)-DO3A sodium is a Mn(II) complex and a potential alternative to Gd-based MRI contrast agents[1].

Mn007 is a potent inhibitor of bovine pancreatic DNase I, with the IC50 of 45 μM, by forming molecular aggregation. Mn007 shows suppression of S. pyogenes growth in human whole blood[1].

MN1 Human Pre-designed siRNA Set A contains three designed siRNAs for MN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MNAT1 Human Pre-designed siRNA Set A contains three designed siRNAs for MNAT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MND1 Human Pre-designed siRNA Set A contains three designed siRNAs for MND1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MNDA Human Pre-designed siRNA Set A contains three designed siRNAs for MNDA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MNI-caged-L-glutamate TFA is a reagent that can release neuroactive amino acids quickly and efficiently[1].

MNK-IN-4 (compound D25) is a potent and selective MNK inhibitor for the treatment of sepsis-related acute splenic injury[1].

MNK1/2-IN-7 (compound 20j) is an orally available inhibitor of MNK1/2 with anticancer activity and hERG safety. MNK1/2-IN-7 also inhibits the phosphorylation of eIF4E, inhibiting the MNK/eIF4E signaling pathway and cancer cell proliferation. MNK1/2-IN-7 is synergistic with Ibrutinib (HY-109970).[15][1].

MNS1 Human Pre-designed siRNA Set A contains three designed siRNAs for MNS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MNT Human Pre-designed siRNA Set A contains three designed siRNAs for MNT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MNX1 Human Pre-designed siRNA Set A contains three designed siRNAs for MNX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOAP1 Human Pre-designed siRNA Set A contains three designed siRNAs for MOAP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOB1A Human Pre-designed siRNA Set A contains three designed siRNAs for MOB1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOB1B Human Pre-designed siRNA Set A contains three designed siRNAs for MOB1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOB2 Human Pre-designed siRNA Set A contains three designed siRNAs for MOB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOB3B Human Pre-designed siRNA Set A contains three designed siRNAs for MOB3B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOB4 Human Pre-designed siRNA Set A contains three designed siRNAs for MOB4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOBP Human Pre-designed siRNA Set A contains three designed siRNAs for MOBP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOCOS Human Pre-designed siRNA Set A contains three designed siRNAs for MOCOS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOCS1 Human Pre-designed siRNA Set A contains three designed siRNAs for MOCS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOCS2 Human Pre-designed siRNA Set A contains three designed siRNAs for MOCS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOCS3 Human Pre-designed siRNA Set A contains three designed siRNAs for MOCS3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Moexipril-d3 is deuterated labeled Moexipril (HY-117281). Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila hydrochloride. Moexipril exhibits antihypertensive and neuroprotective effects[1]–[4].

MOG Human Pre-designed siRNA Set A contains three designed siRNAs for MOG gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOGAT1 Human Pre-designed siRNA Set A contains three designed siRNAs for MOGAT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOGAT2 Human Pre-designed siRNA Set A contains three designed siRNAs for MOGAT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MOK Human Pre-designed siRNA Set A contains three designed siRNAs for MOK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Molindone (hydrochloride) (Standard) is the analytical standard of Molindone (hydrochloride). This product is intended for research and analytical applications.

Molsidomine (Standard) is the analytical standard of Molsidomine. This product is intended for research and analytical applications. Molsidomine is an orally available, long-acting vasodilator that is metabolized in the liver to the active metabolite Linsidomine, an unstable compound that releases NO and acts as a vasodilator.

MON1A Human Pre-designed siRNA Set A contains three designed siRNAs for MON1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MON2 Human Pre-designed siRNA Set A contains three designed siRNAs for MON2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Monatepil maleate (AJ-2615) is a potent and orally active Ca2+-channel antagonist and a noncompetitive ACAT inhibitor. Monatepil maleate decreases blood pressure and improves plasma lipid metabolism. Monatepil maleate has the potential for the research of hyperlipidemia[1][2].